Literature DB >> 21704829

Is survivin the potential Achilles' heel of cancer?

Alvaro Lladser1, Carlos Sanhueza, Rolf Kiessling, Andrew F G Quest.   

Abstract

Survivin, the smallest member of the inhibitors of apoptosis proteins (IAPs), plays an important role in the control of apoptosis, cell division, and cell migration/metastasis. Survivin is expressed and required for normal fetal development but is then generally no longer present in most adult tissues. However, reexpression of survivin is observed in numerous human cancers where presence of the protein is associated with enhanced proliferation, metastasis, poor prognosis, and decreased patient survival. Given the relatively selective expression in cancer cells, but not in normal tissue (tumor-associated antigen), and its importance in tumor cell biology, survivin has emerged as an attractive target for cancer treatment. Here, we discuss some aspects of survivin biology by focusing on why the protein appears to be so important for cancer cells and then discuss strategies that harness this dependence to eradicate tumors and situate survivin as a potential Achilles' heel of cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704829     DOI: 10.1016/B978-0-12-385524-4.00001-5

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  21 in total

1.  The involvement of survivin in insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer.

Authors:  Chengjun Li; Jinbao Li; Dawei Wu; Gang Han
Journal:  Tumour Biol       Date:  2015-08-14

Review 2.  The emerging role of exosomes in survivin secretion.

Authors:  Salma Khan; Heather Ferguson Bennit; Nathan R Wall
Journal:  Histol Histopathol       Date:  2014-07-14       Impact factor: 2.303

3.  Modulation of the Inhibitors of Apoptosis Proteins (IAPs) Activities for Cancer Treatment.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2017-04-11       Impact factor: 4.345

4.  Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth.

Authors:  Astrid Weiss; Boris Brill; Corina Borghouts; Natalia Delis; Laura Mack; Bernd Groner
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

Review 5.  Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.

Authors:  Bernd Groner; Axel Weber; Laura Mack
Journal:  Bioengineered       Date:  2012-07-24       Impact factor: 3.269

6.  TGF-β Regulates Survivin to Affect Cell Cycle and the Expression of EGFR and MMP9 in Glioblastoma.

Authors:  Wenliang Chen; Xiao Zhong; Yi Wei; Yun Liu; Quan Yi; Genshui Zhang; Lishan He; Fajiang Chen; Yingping Liu; Jiandong Luo
Journal:  Mol Neurobiol       Date:  2015-02-17       Impact factor: 5.590

7.  Survivin in breast cancer-derived exosomes activates fibroblasts by up-regulating SOD1, whose feedback promotes cancer proliferation and metastasis.

Authors:  Kangdi Li; Ting Liu; Jie Chen; Huying Ni; Wenhua Li
Journal:  J Biol Chem       Date:  2020-07-24       Impact factor: 5.157

8.  SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial-mesenchymal transition via ERK and PI3K/AKT pathway.

Authors:  Peng Yang; Gang Wang; Hongjun Huo; Qiang Li; Yan Zhao; Yuanhang Liu
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

9.  SDF-1/CXCR4 Axis Regulates Cell Cycle Progression and Epithelial-Mesenchymal Transition via Up-regulation of Survivin in Glioblastoma.

Authors:  Anyan Liao; Ranran Shi; Yuliang Jiang; Suqing Tian; Panpan Li; Fuxi Song; Yalan Qu; Jinna Li; Haiqin Yun; Xiangshan Yang
Journal:  Mol Neurobiol       Date:  2014-11-25       Impact factor: 5.590

10.  Fowlpox-based survivin vaccination for malignant mesothelioma therapy.

Authors:  Pietro Bertino; Maddalena Panigada; Elisa Soprana; Valentina Bianchi; Sabrina Bertilaccio; Francesca Sanvito; Aaron H Rose; Haining Yang; Giovanni Gaudino; Peter R Hoffmann; Antonio Siccardi; Michele Carbone
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.